Pulmonary Rehabilitation in Non-Cystic Fibrosis Bronchiectasis

Status Recruiting

Clinical Trial Summary

The purpose of this study is to assess the effect of pulmonary rehabilitation on the transport of secretions, inflammation and respiratory resistance, and its repercussions on the quality of life in patients with bronchiectasis.

Clinical Trial Description

Bronchiectasis is characterized by pathological and irreversible dilation of bronchi caused by the inefficient removal of secretions and microorganisms and the perpetuation of inflammatory processes induced by chronic or recurrent infections, causing more damage to the airways that result in infections, and greater lesion airways and lung parenchyma. Pulmonary rehabilitation in people with bronchiectasis aims to improve exercise capacity, through effects on aerobic capacity and peripheral muscles, and to improve disease control and quality of life. The aim this study is to evaluate the effects of pulmonary rehabilitation on the transport of secretions, inflammation and respiratory resistance, and its repercussions on the quality of life in patients with bronchiectasis. In this study 60 volunteers, of both sexes, aged between 18-60 years, adequate the inclusion criteria, which will be assessed by lung function tests, the saccharin transport time, the inflammatory markers in the airways, the respiratory system resistance and quality of life scales. Volunteers will be randomly divided in pulmonary rehabilitation (PRG) and control groups (CG) that will be subdivided in bronchiectasis and healthy subgroups. In the PRG group they will receive supervised physical training twice a week and will be instructed to adopt a routine of home exercises, while CG will be informed about the benefits of physical activities. All volunteers will be evaluated after 8 weeks of the baseline and at the end of the research. Data evolution will be collected from medical records and notes of the medical team and physical therapy that will follow the routine of these participants ;

Study Design

Related Conditions & MeSH terms

Bronchiectasis

Clinical Trial Details

NCT number	NCT02823587
Study type	Interventional
Source	University of Sao Paulo
Contact	Ada C Gastaldi, PhD
Phone	55 16 33150473
Email	ada@fmrp.usp.br
Status	Recruiting
Phase	N/A
Start date	July 2016
Completion date	December 2019

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT05034900` - Does Addition of Oscillatory Positive Expiratory Pressure (OPEP) Device to a Chest Physiotherapy Program Provide Further Health Benefits in Children With Bronchiectasis?	N/A
Recruiting	`NCT04101448` - Prevalence of Bronchiectasis in COPD Patients
Withdrawn	`NCT03376204` - Pain Mechanisms in Patients With Bronchiectasis
Completed	`NCT02550821` - Comparison of Physical Activity Level Between Patients With Bronchiectasis and Healthy Subjects
Completed	`NCT02656992` - Effects of High Intensity Inspiratory Muscle Training on Exercise Capacity in Patients With Bronchiectasis	N/A
Completed	`NCT02282202` - Evaluation of Oscillatory Positive Expiratory Pressure (oPEP) in Bronchiectasis and COPD	N/A
Completed	`NCT01615484` - Ex-vivo Perfusion and Ventilation of Lungs Recovered From Non-Heart-Beating Donors to Assess Transplant Suitability	N/A
Completed	`NCT02048397` - Pulmonary Rehabilitation Program (PRP) Versus PRP Plus Nutritional Supplementation in Patients With Bronchiectasis	N/A
Recruiting	`NCT01761214` - Bacteriology and Inflammation in Bronchiectasis	N/A
Recruiting	`NCT02527486` - Seoul National University Airway Registry	N/A
Completed	`NCT01578681` - ELTGOL and Bronchiectasis. Respiratory Therapy	N/A
Completed	`NCT01854788` - 3 Airway Clearance Techniques in Non Cystic Fibrosis Bronchiectasis	N/A
Completed	`NCT00769119` - A Phase II , Placebo-controlled Study to Assess Efficacy of 28 Day Oral AZD9668 in Patients With Bronchiectasis	Phase 2
Terminated	`NCT00524095` - Bronchiectasis in Chronic Obstructive Pulmonary Disease (COPD) Patients: Role of Prophylaxis	Phase 2
Completed	`NCT01117493` - Expert Patient Self-management Programme Versus Usual Care in Bronchiectasis	N/A
Recruiting	`NCT00129350` - Assessment of Heart and Heart-Lung Transplant Patient Outcomes Following Pulmonary Rehabilitation	Phase 1
Completed	`NCT00656721` - Respiratory Mechanics Effects of Flutter Valve in Bronchiectasis Patients	N/A
Completed	`NCT04081740` - Biological Determinants of Sputum Rheology in Chronic Airway Diseases
Enrolling by invitation	`NCT02546297` - Comparisons of Inhaled LAMA or LAMA+LABA or ICS+LABA for COPD With Bronchiectasis	Phase 4
Completed	`NCT03628456` - Effect of HFCWO Vests on Spirometry Measurements	N/A

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.